-
2
-
-
84875859346
-
Agitation and aggression in people with Alzheimers disease
-
Ballard C, Corbett A. Agitation and aggression in people with Alzheimers disease. Curr. Opin. Psychiatry 2013; 26(3): 252-259.
-
(2013)
Curr. Opin. Psychiatry
, vol.26
, Issue.3
, pp. 252-259
-
-
Ballard, C.1
Corbett, A.2
-
3
-
-
46749095495
-
Clinical symptom responses to atypical antipsychotic medications in Alzheimers disease: Phase 1 outcomes from the CATIE-AD effectiveness trial
-
Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG. et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimers disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am. J. Psychiatry 2008; 165(7): 844-854.
-
(2008)
Am. J. Psychiatry
, vol.165
, Issue.7
, pp. 844-854
-
-
Sultzer, D.L.1
Davis, S.M.2
Tariot, P.N.3
Dagerman, K.S.4
Lebowitz, B.D.5
Lyketsos, C.G.6
-
4
-
-
84861936838
-
Choice of observational study design impacts on measurement of antipsychotic risks in the elderly: A systematic review
-
Pratt N, Roughhead EE, Salter A, Ryan P. Choice of observational study design impacts on measurement of antipsychotic risks in the elderly: A systematic review. BMC Med. Res. Methodol. 2012; 12: 72.
-
(2012)
BMC Med. Res. Methodol
, vol.12
, pp. 72
-
-
Pratt, N.1
Roughhead, E.E.2
Salter, A.3
Ryan, P.4
-
5
-
-
33749618085
-
Effectiveness of atypical antipsychotic drugs in patients with Alzheimers disease
-
Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS. et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimers disease. N. Engl. J. Med. 2006; 355(15): 1525-1538.
-
(2006)
N. Engl. J. Med
, vol.355
, Issue.15
, pp. 1525-1538
-
-
Schneider, L.S.1
Tariot, P.N.2
Dagerman, K.S.3
Davis, S.M.4
Hsiao, J.K.5
Ismail, M.S.6
-
6
-
-
33745737632
-
Neuroleptic drugs in dementia: Benefits and harm
-
Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. Nat. Rev. Neurosci. 2006; 7(6):492-500.
-
(2006)
Nat. Rev. Neurosci
, vol.7
, Issue.6
, pp. 492-500
-
-
Ballard, C.1
Howard, R.2
-
7
-
-
84867608044
-
Relapse risk after discontinuation of risperidone in Alzheimers disease
-
Devanand DP, Mintzer J, Schultz SK, Andrews HF, Sultzer DL, de la Pena D. et al. Relapse risk after discontinuation of risperidone in Alzheimers disease. N. Engl. J. Med. 2012; 367(16): 1497-1507.
-
(2012)
N. Engl. J. Med
, vol.367
, Issue.16
, pp. 1497-1507
-
-
Devanand, D.P.1
Mintzer, J.2
Schultz, S.K.3
Andrews, H.F.4
Sultzer, D.L.5
De La Pena, D.6
-
8
-
-
0033799993
-
Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial
-
Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN. et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch. Gen. Psychiatry 2000; 57(10): 968-976.
-
(2000)
The HGEU Study Group. Arch. Gen. Psychiatry
, vol.57
, Issue.10
, pp. 968-976
-
-
Street, J.S.1
Clark, W.S.2
Gannon, K.S.3
Cummings, J.L.4
Bymaster, F.P.5
Tamura, R.N.6
-
9
-
-
33644922637
-
Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-Analysis of randomized, placebo-controlled trials
-
Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-Analysis of randomized, placebo-controlled trials. Am. J. Geriatr. Psychiatry 2006; 14(3): 191-210.
-
(2006)
Am. J. Geriatr. Psychiatry
, vol.14
, Issue.3
, pp. 191-210
-
-
Schneider, L.S.1
Dagerman, K.2
Insel, P.S.3
-
10
-
-
0032966714
-
Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial
-
Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. Risperidone Study Group. J. Clin. Psychiatry 1999; 60(2): 107-115.
-
(1999)
Risperidone Study Group. J. Clin. Psychiatry
, vol.60
, Issue.2
, pp. 107-115
-
-
Katz, I.R.1
Jeste, D.V.2
Mintzer, J.E.3
Clyde, C.4
Napolitano, J.5
Brecher, M.6
-
11
-
-
26844538114
-
Risk of death with atypical antipsychotics drug treatment for dementia: Meta-Analysis of randomized placebo-controlled trials
-
Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotics drug treatment for dementia: meta-Analysis of randomized placebo-controlled trials. JAMA 2012; 294(15): 1934-1943.
-
(2012)
JAMA
, vol.294
, Issue.15
, pp. 1934-1943
-
-
Schneider, L.S.1
Dagerman, K.S.2
Insel, P.3
-
12
-
-
28244431743
-
Risk of death in elderly users of conventional vs atypical antipsychotic medications
-
Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH. et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N. Engl. J. Med. 2005; 353(22): 2335-2341.
-
(2005)
N. Engl. J. Med
, vol.353
, Issue.22
, pp. 2335-2341
-
-
Wang, P.S.1
Schneeweiss, S.2
Avorn, J.3
Fischer, M.A.4
Mogun, H.5
Solomon, D.H.6
-
14
-
-
84863115465
-
Risk of mortality among individual antipsychotics in patients with dementia
-
Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C. et al. Risk of mortality among individual antipsychotics in patients with dementia. Am. J. Psychiatry 2012; 169: 71-79.
-
(2012)
Am. J. Psychiatry
, vol.169
, pp. 71-79
-
-
Kales, H.C.1
Kim, H.M.2
Zivin, K.3
Valenstein, M.4
Seyfried, L.S.5
Chiang, C.6
-
15
-
-
0035674311
-
A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients
-
Chan WC, Lam LC, Choy CN, Leung VP, Li SW, Chiu HF. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int. J. Geriatr. Psychiatry 2001; 16(12): 1156-1162.
-
(2001)
Int. J. Geriatr. Psychiatry
, vol.16
, Issue.12
, pp. 1156-1162
-
-
Chan, W.C.1
Lam, L.C.2
Choy, C.N.3
Leung, V.P.4
Li, S.W.5
Chiu, H.F.6
-
16
-
-
80053215800
-
Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: A systematic review and meta-Analysis
-
12
-
Maher AR, Maglione M, Bagley S, Suttorp M, Hu JH, Ewing B. et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: A systematic review and meta-Analysis. JAMA 2011; 28; 306(12): 1359-1369.
-
(2011)
JAMA
, vol.28
, Issue.306
, pp. 1359-1369
-
-
Maher, A.R.1
Maglione, M.2
Bagley, S.3
Suttorp, M.4
Hu, J.H.5
Ewing, B.6
-
17
-
-
34447118214
-
Aggressive behavior and neuroleptic medication are associated with increased number of alpha1-Adrenoceptors in patients with Alzheimer disease
-
Sharp SI, Ballard CG, Chen CP, Francis PT. Aggressive behavior and neuroleptic medication are associated with increased number of alpha1-Adrenoceptors in patients with Alzheimer disease. Am. J. Geriatr. Psychiatry 2007; 15(5): 435-437.
-
(2007)
Am. J. Geriatr. Psychiatry
, vol.15
, Issue.5
, pp. 435-437
-
-
Sharp, S.I.1
Ballard, C.G.2
Chen, C.P.3
Francis, P.T.4
-
18
-
-
84936862890
-
Noradrenergic dysfunction in Alzheimers disease
-
Gannon M, Che P, Chen Y, Jiao K, Roberson ED, Wang Q. Noradrenergic dysfunction in Alzheimers disease. Front. Neurosci. 2015; 9: 220. doi: 10.3389/fnins.2015.00220.
-
(2015)
Front. Neurosci
, vol.9
, pp. 220
-
-
Gannon, M.1
Che, P.2
Chen, Y.3
Jiao, K.4
Roberson, E.D.5
Wang, Q.6
-
19
-
-
69449092485
-
Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression
-
Wang LY, Shofer JB, Rohde K, Hart KL, Hoff DJ, McFall YH. et al. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am. J. Geriatr. Psychiatry 2009; 17(9): 744-751.
-
(2009)
Am. J. Geriatr. Psychiatry
, vol.17
, Issue.9
, pp. 744-751
-
-
Wang, L.Y.1
Shofer, J.B.2
Rohde, K.3
Hart, K.L.4
Hoff, D.J.5
McFall, Y.H.6
-
20
-
-
0033945096
-
A retrospective chart review of gabapentin for the treatment of aggressive and agitated behavior in patients with dementias
-
Hawkins JW, Tinklenberg JR, Sheikh JI, Peyser CE, Yesavage JA. A retrospective chart review of gabapentin for the treatment of aggressive and agitated behavior in patients with dementias. Am. J. Geriatr. Psychiatry 2000; 8(3): 221-225.
-
(2000)
Am. J. Geriatr. Psychiatry
, vol.8
, Issue.3
, pp. 221-225
-
-
Hawkins, J.W.1
Tinklenberg, J.R.2
Sheikh, J.I.3
Peyser, C.E.4
Yesavage, J.A.5
-
21
-
-
0346848738
-
Gabapentin for the treatment of behavioural alterations in dementia: Preliminary 15-month investigation
-
Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Gabapentin for the treatment of behavioural alterations in dementia: preliminary 15-month investigation. Drugs Aging 2003; 20(14): 1035-1040.
-
(2003)
Drugs Aging
, vol.20
, Issue.14
, pp. 1035-1040
-
-
Moretti, R.1
Torre, P.2
Antonello, R.M.3
Cazzato, G.4
Bava, A.5
-
22
-
-
0028970069
-
Anticonvulsants attenuate amyloid betapeptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology
-
Mark RJ, Ashford JW, Goodman Y, Mattson MP. Anticonvulsants attenuate amyloid betapeptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology. Neurobiol. Aging 1995; 16(2): 187-198.
-
(1995)
Neurobiol. Aging
, vol.16
, Issue.2
, pp. 187-198
-
-
Mark, R.J.1
Ashford, J.W.2
Goodman, Y.3
Mattson, M.P.4
-
23
-
-
79961230030
-
Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease
-
Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ. et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch. Gen. Psychiatry 2011; 68(8): 853-861.
-
(2011)
Arch. Gen. Psychiatry
, vol.68
, Issue.8
, pp. 853-861
-
-
Tariot, P.N.1
Schneider, L.S.2
Cummings, J.3
Thomas, R.G.4
Raman, R.5
Jakimovich, L.J.6
-
24
-
-
41649103102
-
American Psychiatric Association practice guideline for the treatment of patients with Alzheimers disease and other dementias
-
APA Work Group on Alzheimers Disease and other Dementias
-
APA Work Group on Alzheimers Disease and other Dementias, Rabins PV, Blacker D, Rovner BW, Rummans T, Schneider LS. et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimers disease and other dementias. Second edition. Am. J. Psychiatry 2007; 164(12 supl.): 5-56.
-
(2007)
Second Edition. Am. J. Psychiatry
, vol.164
, Issue.12
, pp. 5-56
-
-
Rabins, P.V.1
Blacker, D.2
Rovner, B.W.3
Rummans, T.4
Schneider, L.S.5
-
25
-
-
0035172216
-
Placebo-controlled study of divalproex sodium for agitation in dementia
-
Porsteinsson AP, Tariot PN, Erb R, Cox C, Smith E, Jakimovich L. et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am. J. Geriatr. Psychiatry 2001; 9(1): 58-66.
-
(2001)
Am. J. Geriatr. Psychiatry
, vol.9
, Issue.1
, pp. 58-66
-
-
Porsteinsson, A.P.1
Tariot, P.N.2
Erb, R.3
Cox, C.4
Smith, E.5
Jakimovich, L.6
-
26
-
-
0036085791
-
Sodium valproate in the treatment of aggressive behavior in patients with dementia-A randomized placebo controlled clinical trial
-
Sival RC, Haffmans PM, Jansen PA, Duursma SA, Eikelenboom P. Sodium valproate in the treatment of aggressive behavior in patients with dementia-A randomized placebo controlled clinical trial. Int. J. Geriatr. Psychiatry 2002; 17(6): 579-585.
-
(2002)
Int. J. Geriatr. Psychiatry
, vol.17
, Issue.6
, pp. 579-585
-
-
Sival, R.C.1
Haffmans, P.M.2
Jansen, P.A.3
Duursma, S.A.4
Eikelenboom, P.5
-
27
-
-
0031944188
-
Serotonin in aging, late-life depression, and Alzheimers disease: The emerging role of functional imaging
-
Meltzer CC, Smith G, DeKosky ST, Pollock BG, Mathis CA, Moore RY. et al. Serotonin in aging, late-life depression, and Alzheimers disease: The emerging role of functional imaging. Neuropsychopharmacology 1998; 18(6): 407-430.
-
(1998)
Neuropsychopharmacology
, vol.18
, Issue.6
, pp. 407-430
-
-
Meltzer, C.C.1
Smith, G.2
DeKosky, S.T.3
Pollock, B.G.4
Mathis, C.A.5
Moore, R.Y.6
-
28
-
-
84894122063
-
Effect of citalopram on agitation in Alzheimer disease: The CitAD randomized clinical trial
-
Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z. et al. Effect of citalopram on agitation in Alzheimer disease: The CitAD randomized clinical trial. JAMA 2014; 311(7): 682-691.
-
(2014)
JAMA
, vol.311
, Issue.7
, pp. 682-691
-
-
Porsteinsson, A.P.1
Drye, L.T.2
Pollock, B.G.3
Devanand, D.P.4
Frangakis, C.5
Ismail, Z.6
-
29
-
-
0036190759
-
Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients
-
Pollock BG, Mulsant BH, Rosen J, Sweet RA, Mazumdar S, Bharucha A. et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am. J. Psychiatry 2002; 159(3): 460-465.
-
(2002)
Am. J. Psychiatry
, vol.159
, Issue.3
, pp. 460-465
-
-
Pollock, B.G.1
Mulsant, B.H.2
Rosen, J.3
Sweet, R.A.4
Mazumdar, S.5
Bharucha, A.6
-
30
-
-
38449107464
-
A doubleblind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia
-
Pollock BG, Mulsant BH, Rosen J, Mazumdar S, Blakesley RE, Houck PR. et al. A doubleblind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am. J. Geriatr. Psychiatry 2007; 15(11): 942-952.
-
(2007)
Am. J. Geriatr. Psychiatry
, vol.15
, Issue.11
, pp. 942-952
-
-
Pollock, B.G.1
Mulsant, B.H.2
Rosen, J.3
Mazumdar, S.4
Blakesley, R.E.5
Houck, P.R.6
-
31
-
-
0031026215
-
A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia
-
Sultzer DL, Gray KF, Gunay I, Berisford MA, Mahler ME. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am. J. Geriatr. Psychiatry 1997; 5(1): 60-69.
-
(1997)
Am. J. Geriatr. Psychiatry
, vol.5
, Issue.1
, pp. 60-69
-
-
Sultzer, D.L.1
Gray, K.F.2
Gunay, I.3
Berisford, M.A.4
Mahler, M.E.5
-
32
-
-
0034649447
-
Treatment of agitation in AD: A randomized, placebo-controlled clinical trial
-
Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE. et al. Treatment of agitation in AD: A randomized, placebo-controlled clinical trial. Neurology 2000; 55(9): 1271-1278.
-
(2000)
Neurology
, vol.55
, Issue.9
, pp. 1271-1278
-
-
Teri, L.1
Logsdon, R.G.2
Peskind, E.3
Raskind, M.4
Weiner, M.F.5
Tractenberg, R.E.6
-
33
-
-
0033980910
-
Cholinesterase inhibitors: A new class of psychotropic compounds
-
Cummings JL. Cholinesterase inhibitors: A new class of psychotropic compounds. Am. J. Psychiatry 2000; 157(1): 4-15.
-
(2000)
Am. J. Psychiatry
, vol.157
, Issue.1
, pp. 4-15
-
-
Cummings, J.L.1
-
34
-
-
34948834261
-
Donepezil for the treatment of agitation in Alzheimers disease
-
Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R. et al. Donepezil for the treatment of agitation in Alzheimers disease. N. Engl. J. Med. 2007; 357(14): 1382-1392.
-
(2007)
N. Engl. J. Med
, vol.357
, Issue.14
, pp. 1382-1392
-
-
Howard, R.J.1
Juszczak, E.2
Ballard, C.G.3
Bentham, P.4
Brown, R.G.5
Bullock, R.6
-
35
-
-
3242775357
-
The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease
-
Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A. et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004; 63(2): 214-219.
-
(2004)
Neurology
, vol.63
, Issue.2
, pp. 214-219
-
-
Holmes, C.1
Wilkinson, D.2
Dean, C.3
Vethanayagam, S.4
Olivieri, S.5
Langley, A.6
-
36
-
-
38049005871
-
Efficacy of memantine on behavioral and psychological symptoms related to dementia: A systematic meta-Analysis
-
Maidment ID, Fox CG, Boustani M, Rodriguez J, Brown RC, Katona CL. Efficacy of memantine on behavioral and psychological symptoms related to dementia: A systematic meta-Analysis. Ann. Pharmacother. 2008; 42(1): 32-38.
-
(2008)
Ann. Pharmacother
, vol.42
, Issue.1
, pp. 32-38
-
-
Maidment, I.D.1
Fox, C.G.2
Boustani, M.3
Rodriguez, J.4
Brown, R.C.5
Katona, C.L.6
-
37
-
-
19144372322
-
Effects of memantine on behavioural symptoms in Alzheimers disease patients: An analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies
-
Gauthier S, Wirth Y, Möbius HJ. Effects of memantine on behavioural symptoms in Alzheimers disease patients: An analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int. J. Geriatr. Psychiatry 2005; 20(5): 459-464.
-
(2005)
Int. J. Geriatr. Psychiatry
, vol.20
, Issue.5
, pp. 459-464
-
-
Gauthier, S.1
Wirth, Y.2
Möbius, H.J.3
-
38
-
-
42249111378
-
Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimers disease: A pooled analysis of 3 studies
-
Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimers disease: A pooled analysis of 3 studies. J. Clin. Psychiatry 2008; 69(3): 341-348.
-
(2008)
J. Clin. Psychiatry
, vol.69
, Issue.3
, pp. 341-348
-
-
Wilcock, G.K.1
Ballard, C.G.2
Cooper, J.A.3
Loft, H.4
-
39
-
-
29244481938
-
Effect of acetaminophen on behavior, well-being, and psychotropic medication use in nursing home residents with moderate-To-severe dementia
-
Chibnall JT, Tait RC, Harman B, Luebbert RA. Effect of acetaminophen on behavior, well-being, and psychotropic medication use in nursing home residents with moderate-To-severe dementia. J. Am. Geriatr. Soc. 2005; 53(11): 1921-1929.
-
(2005)
J. Am. Geriatr. Soc
, vol.53
, Issue.11
, pp. 1921-1929
-
-
Chibnall, J.T.1
Tait, R.C.2
Harman, B.3
Luebbert, R.A.4
-
40
-
-
4344621472
-
Pain assessment and management in persons with dementia
-
Horgas AL, Elliott AF. Pain assessment and management in persons with dementia. Nurs. Clin. North Am. 2004; 39(3): 593-606.
-
(2004)
Nurs. Clin. North Am
, vol.39
, Issue.3
, pp. 593-606
-
-
Horgas, A.L.1
Elliott, A.F.2
-
41
-
-
40549112334
-
ACNP White Paper: Update on use of antipsychotic drugs in elderly persons with dementia
-
Jeste DV, Blazer D, Casey D, Meeks T, Salzman C, Schneider L. et al. ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 2008; 33(5): 957-970.
-
(2008)
Neuropsychopharmacology
, vol.33
, Issue.5
, pp. 957-970
-
-
Jeste, D.V.1
Blazer, D.2
Casey, D.3
Meeks, T.4
Salzman, C.5
Schneider, L.6
-
42
-
-
12844274439
-
Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence
-
Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. JAMA 2005; 293(5): 596-608.
-
(2005)
JAMA
, vol.293
, Issue.5
, pp. 596-608
-
-
Sink, K.M.1
Holden, K.F.2
Yaffe, K.3
-
43
-
-
0037058753
-
The incremental direct costs associated with behavioral symptoms in AD
-
Murman DL, Chen Q, Powell MC, Kuo SB, Bradley CJ, Colenda CC. The incremental direct costs associated with behavioral symptoms in AD. Neurology 2002; 59(11): 1721-1729.
-
(2002)
Neurology
, vol.59
, Issue.11
, pp. 1721-1729
-
-
Murman, D.L.1
Chen, Q.2
Powell, M.C.3
Kuo, S.B.4
Bradley, C.J.5
Colenda, C.C.6
-
44
-
-
46749128245
-
Elderly patients with dementia-related symptoms of severe agitation and aggression: Consensus statement on treatment options, clinical trials methodology, and policy
-
Salzman C, Jeste DV, Meyer RE, Cohen-Mansfield J, Cummings J, Grossberg GT. et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J. Clin. Psychiatry 2008; 69(6): 889-898.
-
(2008)
J. Clin. Psychiatry
, vol.69
, Issue.6
, pp. 889-898
-
-
Salzman, C.1
Jeste, D.V.2
Meyer, R.E.3
Cohen-Mansfield, J.4
Cummings, J.5
Grossberg, G.T.6
|